Chemocentryx Is A Biopharmaceutical Company Founded In 1996 And Based In Mountain Viewcaliforniathe Company Specializes In Discoveringdevelopingand Commercializing Orally Administered Therapeutics For Autoimmune Diseasesinflammatory Disordersand Cancerin October 2022Chemocentryx Was Acquired By Amgen For Approximately $3 8 Billion The Company Is Known For Its Innovative Approach To Targeting The Chemokine And Chemoattractant Systemsfocusing On Oral Therapies That Address Unmet Needs In Immune Mediated Diseasesits Flagship Producttavneosa Avacopan Is An Fda Approved Oral Complement C5A Receptor Inhibitor For Severe Anti Neutrophil Cytoplasmic Auto Antibodyancaassociated Vasculitischemocentryx Has A Robust Pipeline That Includes Candidates For Conditions Such As C3 Glomerulopathyhidradenitis Suppurativaand Lupus Nephritisas Well As Early Stage Therapies For Cancer And Inflammatory Diseaseswith A Commitment To Improving Patient Compliance Through Oral Administrationchemocentryx Has Conducted Over 40 Clinical Trials And Managed A Diverse Pipeline Of More Than 30 Drugsfocusing On Niche Markets With High Unmet Needs
